News
May 14, 2014
CardioCell Scientific Advisory Board Members Present at the 2014 World Congress on Acute Heart Failure
ATHENS, GREECE – WORLD CONGRESS ON ACUTE HEART FAILURE– May 14, 2014 – CardioCell announces presentations by prominent chronic heart failure (CHF) opinion leaders Drs. Javed Butler and Mihai Gheorghiade, members of the company’s scientific advisory board. Dr. Butler is the director of Heart Failure Research and professor of medicine at Emory University. Dr. Gheorghiade is a professor of medicine and surgery and director of Experimental Therapeutics at the Center for Cardiovascular Innovation at Northwestern University Feinberg School of Medicine. Both scientific advisory board members will supervise CardioCell’s upcoming Phase IIa clinical trial using allogeneic stem-cell therapy to treat subjects with CHF.
|
Details: |
The four-day program will focus on investigative approaches to, management of and new therapies for heart failure. Dr. Butler will deliver three talks – “Post discharge assessment after a heart failure hospitalization,” “How to manage co-morbidities in heart failure” and “Unmet needs in HFrEF and HFpEF and possible solutions” – and contribute to “The left atrium in heart failure” workshop. Dr. Gheorghiade’s talks will cover “Congestion as a main target for therapy in worsening heart failure,” “Controversies in acute heart failure,” “Will we fight heart failure differently in the future? New drugs and beyond,” and “Unmet needs in HFrEF and HFpEF and possible solutions.” In addition, he is a panelist on the “Developing new therapies for hospitalized patients with heart failure” workshop. |
|
When: |
May 17-20, 2014 |
|
Where: |
Athens, Greece |
|
Contact: |
Kimberly Stoddard, kimberly@townsendteam.com, (415) 806-5793 |
About CardioCell, LLC
Founded in San Diego, Calif., in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the former Soviet Union, Europe and the United States. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD). For more information, visit www.stemcardiocell.com.